Bio-Rad rolls out SARS CoV-2 standards for Coronavirus Testing
Category: #health  By Nikita Chaurasia  Date: 2020-03-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bio-Rad rolls out SARS CoV-2 standards for Coronavirus Testing
  • The SARS CoV-2 standard has human genomic DNA and synthetic COVID-19 RNA transcripts.
     
  • SARS CoV-2 standard assists laboratories to keep up with the soaring demand for the identification of Coronavirus by helping validate COVID-19 tests.

Amidst the unprecedented fear of Coronavirus (COVID-19), Bio-Rad Laboratories, Inc. has announced the launch of a SARS CoV-2 standard to underpin laboratory assay validation of COVID-19 testing. The testing will be part of its Exact Diagnostics product line as the company is offering the SARS CoV-2 standard to aid labs to expedite access to testing and authenticate their COVID-19 assay results.

The SARS CoV-2 standard has human genomic DNA and synthetic COVID-19 RNA transcripts, thereby enabling laboratories to test the total process of a molecular assay such as amplification, extraction and detection of the virus.

It is worth noting that the (CLIA) Clinical Laboratory Improvement Amendments federal regulatory standards need clinical laboratories to document and build their own specifications of performance meant for test developed in laboratory to make precise and accurate results before the test is implemented.

Dara Wright, Bio-Rad Executive Vice President, highlighted the significance of labs to have access to aptly-defined standards to assist with the authentication of the tests in case of a public health emergency.

Wright stressed that the SARS CoV-2 standard assists laboratories to keep up with the soaring demand for the identification of Coronavirus by helping validate COVID-19 tests.

The press release shared by Bio-Rad states that the Exact Diagnostics product line develops and manufactures an array of innovatively designed molecular diagnostics products to keep abreast with the needs of quality control of assay manufacturers and clinal labs.

Underpinned by offering quality products and services to labs and manufacturers, the diagnostic products intend to improve patient care by helping to assure the validity of screening tests and diagnostic results.

Source credit:

https://www.bio-rad.com/en-in/corporate/newsroom/bio-rad-announces-that-through-its-exact-diagnostics-product-line-company-has-launched-sars-cov-2-standard-for-coronavirus-covid-19-testing?ID=Bio-Rad-Announces-th_1584057675

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Australian researchers discover anti-parasite drug that kills COVID-19
Australian researchers discover anti-parasite drug that kills COVID-19
By Nikita Chaurasia

Researchers at Monash University, Melbourne, have reportedly announced that they discovered that an anti-parasite medicine can kill the novel strain of the coronavirus (SARS-CoV-2) that has currently brought the world to a standstill. In a study pub...

Trump calls for a $2 trillion budget for U.S. infrastructure growth
Trump calls for a $2 trillion budget for U.S. infrastructure growth
By Nikita Chaurasia

U.S. President Donald Trump has reportedly called for a $2 trillion spending budget to repair the and build new and currently crumbling infrastructure including tunnels, bridges, and roads, seizing on the COVID-19 outbreak as well as interest rates t...

Analytics 4 Life reveals new data backing novel method to predict LVEDP
Analytics 4 Life reveals new data backing novel method to predict LVEDP
By Nikita Chaurasia

Analytics 4 Life, one the leading digital health company committed to improving existing diagnostic pathways, has reportedly presented data on its heart failure research at the ACC’s (American College of Cardiology) 69th Annual Scientific Sessi...